Can engineered immune cells tame lupus? new trial hopes so.
NCT ID NCT06465147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment for children and young adults (ages 2-30) with severe lupus that hasn't responded to standard therapies. The treatment involves collecting a patient's own immune cells, engineering them to target and destroy faulty B cells (which drive lupus), and infusing them back. The main goals are to check safety and see if the cell product can be made successfully.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can genetics and environment explain lupus in the gullah population?
- Can a smartphone app bridge the lupus care gap for women of color?